Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Frequently asked questions
What sector does Reviva Pharmaceuticals Holdings Inc. (RVPH) operate in?
Reviva Pharmaceuticals Holdings Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Reviva Pharmaceuticals Holdings Inc. (RVPH) current stock price?
As of the latest data, Reviva Pharmaceuticals Holdings Inc. stock price is $0.47, with a previous close of $0.45. Reviva Pharmaceuticals Holdings Inc. gained $0.02 in the last trading session, representing a 4.44% increase.
What is Reviva Pharmaceuticals Holdings Inc. (RVPH) current market capitalization?
Reviva Pharmaceuticals Holdings Inc. market cap is approximately 6.16 million.
What is Reviva Pharmaceuticals Holdings Inc. (RVPH) Earnings Per Share (EPS)?
The trailing EPS is -$3.33, and the forward EPS is -$1.90.
What is Reviva Pharmaceuticals Holdings Inc. (RVPH) EBITDA?
Reviva Pharmaceuticals Holdings Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.19 million.
Does Reviva Pharmaceuticals Holdings Inc. (RVPH) pay dividends?
No. Reviva Pharmaceuticals Holdings Inc. does not pay a dividend.
When is Reviva Pharmaceuticals Holdings Inc. (RVPH) next earnings report?
Reviva Pharmaceuticals Holdings Inc. is expected to release its next earnings report on June 30, 2026.
What is Reviva Pharmaceuticals Holdings Inc. (RVPH) beta (volatility) score?
Reviva Pharmaceuticals Holdings Inc. has a beta of 0.489, indicating lower volatility than the overall market.
